CrowdStrike's 2025 data shows attackers breach AI systems in 51 seconds. Field CISOs reveal how inference security platforms ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals Inc has faced significant challenges in its financial performance, highlighted by a sharp decline in revenue growth, which fell to -32.98% in Q3 2025 from +30.14% in Q2 2025.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

Abstract: This letter presents a novel method for environmental exploration that takes safety into account in unknown areas by using recursive Gaussian process regression (RGPR). Safety in unknown ...

Abstract: Heterogeneous device-edge-cloud computing infrastructures have become the backbone of modern telecommunication operators and Wide Area Networks (WANs), providing multi-tier computational ...

Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.